Dual antiplatelet therapy duration after percutaneous coronary intervention with contemporary drug-eluting stents: A systematic review and network meta-analysis of randomized trials
Admire Hlupeni, Mehran Jalilzadehbinazar, Rayvlin J Liceralde, Hussain A M Khan, Ravi Donepudi, Shilpkumar Arora · 2026
Read Dual antiplatelet therapy duration after percutaneous coronary intervention with contemporary drug-eluting stents: A systematic review and network meta-analysis of randomized trials by Admire Hlupeni, Mehran Jalilzadehbinazar, Rayvlin J Liceralde, Hussain A M Khan, Ravi Donepudi, Shilpkumar Arora (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357462.txt.
Description
Admire Hlupeni and co-authors pool results from randomized trials to ask how long patients should take two blood-thinning drugs after a stent opens a heart artery. Long courses prevent clots but raise bleeding risk, and modern stents may need shorter cover. Their network analysis compares one, three, six, and twelve month courses across many trials with tens of thousands of patients.
Shorter courses matched the year-long course on major heart events, with no clear penalty at any shorter length. Bleeding, however, fell clearly with one and three month courses, and the three month option ranked best at balancing both risks. Hlupeni and colleagues say the evidence supports shorter therapy for many patients with current stents, chosen with their doctors.
Catalog record
| CREATOR | Admire Hlupeni, Mehran Jalilzadehbinazar, Rayvlin J Liceralde, Hussain A M Khan, Ravi Donepudi, Shilpkumar Arora |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34473 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |